MED19 alters AR occupancy and gene expression in prostate cancer cells, driving MAOA expression and growth under low androgen

Abstract excerpt

Androgen deprivation therapy (ADT) is a mainstay of prostate cancer treatment, given the dependence of prostate cells on androgen and the androgen receptor (AR). However, tumors become ADT-resistant, and there is a need to understand the mechanism. One possible mechanism is the upregulation of AR co-regulators, although only a handful have been definitively linked to disease. We previously identified the Mediator...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Estrogen and related hormone effects
• Share to Hormonal and reproductive studies
• Share to Prostate Cancer Treatment and Research